An interventional study of perioral sensory motor stimulation in Preterm Birth, Tube Feeding and Swallowing Disorder, sponsored by Fatima Memorial Hospital. Completed at 1 site in Pakistan. Open to participants aged 30 Weeks to 34 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-02.
Sponsored by Fatima Memorial Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Premature Birth with a site in Pakistan — 4 open to participants now, 5 under way, 1 of them phase 3. Premature Birth · Pakistan.
Among the 24 studies in Premature Birth with a site in Pakistan, this one is the 10th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2022, is one of 15 with no phase, and was the 10th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →4 of the 24 studies in Premature Birth with a site in Pakistan are open now. Recruiting first, the newest first:
Aga Khan University · Sites in Pakistan
Ages 0 hrs–6 hrs
NICHD Global Network for Women's and Children's Health · Sites in Pakistan, Bangladesh, Democratic Republic of the Congo and 3 more countries
Ages 18–49 · Women only · Healthy volunteers
Aga Khan University · Sites in Pakistan
Ages 18+ · Women only · Healthy volunteers
Indiana University · Sites in Pakistan, United States, Argentina and 30 more countries
Ages 0 min–2 wk
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 30 Weeks to 34 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 123 across the 20 interventional studies, 3,613 across the 4 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 24 has an industry lead sponsor. The 10 most frequent:
Fatima Memorial Hospital is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Fatima Memorial Hospital has 1 study filed under Premature Birth — fewer than ten, so there is no comparison to draw.
3 of the studies in Premature Birth with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT06957769Aga Khan UniversityBiological Impacts of Rising Temperatures on Maternal, Fetal, and Newborn Health: A Cohort Study (BIRTH Cohort) | 2027-06-30 |
| NCT07837141Aga Khan UniversityNoninvasive High Frequency Oscillatory Ventilation Versus Nasal Intermittent Mandatory Ventilation for Respiratory Distress Syndrome in Preterm Neonates | 2027-11-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Premature Birth with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hypothesis
Preterm babies who receive sensory motor stimulation from their mothers as compared to trained nurses will
Aim To determine the maternal role in sensory-motor stimulation for oral feed establishment in preterm neonates Objective
Data Collection All on going and related trials for this intervention shall be registered in the ClinicalTrials.gov. Study shall be conducted after ethical approval from IRB. All participants shall be enrolled after written informed consent from mothers after approval from attending neonatologist (annexure 2). All relevant maternal and neonatal data shall be collected on a specially designed proforma (annexure 3) with following details
Part 4: Oral feeding skill (OFS) assessment adapted from the model presented by Lau and Smith (p). All parameters shall be recorded twice a day for D1, D2, and D3 separately. It includes
According to this oral feeding ability can be classified into four levels depending upon the level of maturity in ascending order as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
* Maternal involvement shall be in three stages for the intervention group as * Observer status * Performing under supervision * Independent * Study groups for sensory motor stimulation (5 minutes) + pacifier (2 minutes) Intervention group (Group I): by mothers 1. T1: Nurses performing all steps while mother observer status 2. T2: Nurses perform all steps in front of the mother and a pacifier will be offered by the mother 3. D1: Mother performs all steps and oral milk shall be offered by the nurse while the mother observes. 4. D2: Mother performing all steps and offering oral milk while the nurse is supervising 5. D3: Mother performing all steps independently
Other: perioral sensory motor stimulation
All steps will be the same as the intervention group and shall be performed by staff nurses
Other: perioral sensory motor stimulation
Step 1 - 6 over 5 minutes 1 With the help of the index finger, on the external surface of the cheek, make a circle starting from the angle of the mouth towards the ear then back 7x each cheek 2 While holding both sides of the cheek with help of the thumb and index finger repeat step 1 7x each cheek 3 Move index finger from one corner to opposite one over both lips separately 7x each lip 4 Gentle massage and compress the gums from center to back of mouth 7x each half of the gum 5 Move the finger from front to back on the hard palate while applying gentle pressure 7x 6 Displace the center of the tongue with gentle pressure 7x 7 Offer pacifier at the end 2 minutes Note: 7x means 7 times
Transition Time to Full Oral Feeding
Time interval between commencement of perioral sensory stimulation on D1 to establishment of full oral feed in both groups. It was done daily till 14th day of perioral sensory motor stimulation. Transition time to full oral feeding was the day at which baby was able to take oral feed of volume of 120-140ml/kg/day.
Time frame: Expected time of oral feed establishment
Improvement (Change) in Efficiency in Oral Feed Establishment
According to this efficiency in oral feed establishment in terms of amount and time is determined for the intervention group vs the control group. It can be classified into four levels depending upon the level of maturity in ascending order as follows: * Level 1: PRO \< 30% and RT \< 1.5 ml/min * Level 2: PRO \< 30% and RT ≥ 1.5 ml/min * Level 3: PRO ≥ 30% and RT \< 1.5 ml/min * Level 4: PRO ≥ 30% and RT ≥ 1.5 ml/min For all neonates, efficacy was measured at 11.00 am and 5.00 pm following sensory motor stimulation for both groups till achievement of full oral feed.
Time frame: For record purpose in this study results, efficacy level was noted as L4 on the following days D1, D2, D3, D5, D7 and D14
•Adverse Outcome Monitoring
monitor for any adverse events like cough, breath holding, chocking, aspiration, tachycardia, and or bradycardia with 1. stimulation 2. feed Adverse outcome monitoring as non-life threatening adverse events including cough, tachycardia HR 180-200/min, bradycardia HR120 - 100/min, , tachypnea RR 60 - 70/min while maintaining SpO2 of \>90% at room air
Time frame: Adverse events were noted on D1, D2,D3,D5,D7 and D14
•Adverse Events Monitoring
monitor for any adverse events like cough, breath holding, chocking, aspiration, tachycardia, and or bradycardia with 1. stimulation 2. feed Adverse outcome monitoring as non-life threatening adverse events including cough, tachycardia HR 180-200/min, bradycardia HR120 - 100/min, , tachypnea RR 60 - 70/min while maintaining SpO2 of \>90% at room air
Time frame: Adverse events were noted on D1, D2,D3,D5,D7 and D14
• Total Volume Taken During Each Feeding
It is the measure of how much feed has been taken orally out of total feed prescribed for each feeding
Time frame: It was noted on D1, D2, D3, D5, D7 and D14
• Volume Taken During the First 5 Min of Feeding (ml) VT5
during each feed taken orally by neonate VT5 is the amount of feed was taken by neonate during first 5 minutes
Time frame: Volume taken during the first 5 min of feeding (ml) VT5 was measured on D1, D2, D3, D5, D7 and D14
•Rate of Transfer (RT) ml/Min
RT is the time taken by neonate to finish oral feed
Time frame: RT was measured on D1, D2, D3, D5, D7 and D14
• Overall Transfer (OT Percent) Volume Taken/Total Volume Prescribed
trend towards oral feed establishment and is measured as overall transfer of milk yo oral out of total amount prescribed
Time frame: OT was measured on D1, D2, D3, D5, D7 and D14
• Proficiency(PRO Percent) Volume Taken During the First 5 Min/Total Volume Prescribed
how much amount of milk is taken during first 5 minutes while administering oral feeding
Time frame: PRO % was measured on D1, D2, D3, D5, D7 and D14
• Neonates Feeding With SSB Coordination
number of neonates who are feeding well and showing coordinated pattern of suck swallow and breath (SSB)
Time frame: It was measured on D1, D2, D3, D5, D7 and D14
The study period spans 16 months (March 2022 - July 2023), in the department of Neonatology, Fatima Memorial Hospital, Lahore. All preterm of gestation age 28 to 34 weeks, admitted to NICU during the study period after seeking consent from parents or guardians were enrolled. All neonates having major anomalies incompatible with life, cleft lip and palate, genetic disorders, IVH (grade III \& IV), HsPDA, hemodynamic instability, NEC (stage II \& III) or anemia requiring transfusion were excluded.
| Milestone | Intervention Group (Group 1) | Control Group (Group 2) |
|---|---|---|
| Started | 65 | 65 |
| Execution of sensory motor stimulation | 54 | 53 |
| Completed | 49 | 48 |
| Not completed | 16 | 17 |
| Withdrew: Protocol violation | 3 | 3 |
| Withdrew: Failure to establish gavage feed by 2 weeks of chronological age | 4 | 2 |
| Withdrew: Hspda requiring antifailure therapy | 1 | 2 |
| Withdrew: Continued need of mechanical ventilation | 2 | 3 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Ivh (g iii & iv) | 2 | 1 |
| Withdrew: Nec (stage ii & iii) | 2 | 3 |
Time interval between commencement of perioral sensory stimulation on D1 to establishment of full oral feed in both groups. It was done daily till 14th day of perioral sensory motor stimulation. Transition time to full oral feeding was the day at which baby was able to take oral feed of volume of 120-140ml/kg/day.
| days | Intervention Group (Group 1) | Control Group (Group 2) |
|---|---|---|
| Transition Time to Full Oral Feeding | 10 (7 to 13) | 9 (7 to 13) |
According to this efficiency in oral feed establishment in terms of amount and time is determined for the intervention group vs the control group. It can be classified into four levels depending upon the level of maturity in ascending order as follows: * Level 1: PRO \< 30% and RT \< 1.5 ml/min * Level 2: PRO \< 30% and RT ≥ 1.5 ml/min * Level 3: PRO ≥ 30% and RT \< 1.5 ml/min * Level 4: PRO ≥ 30% and RT ≥ 1.5 ml/min For all neonates, efficacy was measured at 11.00 am and 5.00 pm following sensory motor stimulation for both groups till achievement of full oral feed.
| Participants | Control Group (Group 2) | Intervention Group (Group 1) |
|---|---|---|
| L4 efficacy by D1-3 | 0 | 0 |
| L4 efficacy by D5 | 9 | 12 |
| L4 efficacy by D7 | 15 | 16 |
| L4 efficacy by D14 | 36 | 35 |
monitor for any adverse events like cough, breath holding, chocking, aspiration, tachycardia, and or bradycardia with 1. stimulation 2. feed Adverse outcome monitoring as non-life threatening adverse events including cough, tachycardia HR 180-200/min, bradycardia HR120 - 100/min, , tachypnea RR 60 - 70/min while maintaining SpO2 of \>90% at room air
| Participants | Control Group (Group 2) | Intervention Group (Group 1) |
|---|---|---|
| Adverse events D1 | 31 | 36 |
| Adverse events D2 | 14 | 14 |
| Adverse events D3 | 12 | 12 |
| Averse events D5 | 0 | 2 |
| Adverse events D7 & 14 | 0 | 0 |
It is the measure of how much feed has been taken orally out of total feed prescribed for each feeding
| ml | Control Group (Group 2) | Intervention Group (Group 1) |
|---|---|---|
| Oral feed volume/feed on D1 | 2 (2 to 7) | 2 (2 to 7) |
| Oral feed volume/feed on D2 | 3 (2 to 7) | 5 (2 to 9) |
| Oral feed volume/feed on D3 | 4 (3 to 10) | 7 (3 to 11) |
| Oral feed volume/feed on D5 | 6.5 (5 to 15) | 8 (5 to 15) |
| Oral feed volume/feed on D7 | 7.5 (7 to 20) | 9 (7 to 18) |
| Oral feed volume/feed on D14 | 15.5 (14 to 22) | 15.5 (13 to 20.5) |
during each feed taken orally by neonate VT5 is the amount of feed was taken by neonate during first 5 minutes
| ml | Control Group (Group 2) | Intervention Group (Group 1) |
|---|---|---|
| VT5 on D1 | 2 (1.25 to 4) | 2 (1 to 4.5) |
| VT5 on D2 | 3 (2 to 5) | 3 (2 to 6) |
| VT5 on D3 | 3 (2 to 7) | 3 (2 to 7) |
| VT5 on D5 | 5 (4 to 8) | 5 (4 to 9) |
| VT5 on D7 | 7 (6 to 10) | 7 (5.5 to 11) |
| VT5 on D14 | 10 (9 to 10) | 10 (9 to 12.5) |
RT is the time taken by neonate to finish oral feed
| ml/min | Control Group (Group 2) | Intervention Group (Group 1) |
|---|---|---|
| RT on D1 | 0.42 (0.28 to 0.70) | 0.42 (0.24 to 0.85) |
| RT on D2 | 0.71 (0.70 to 1.0) | 0.70 (0.59 to 1.0) |
| RT on D3 | 0.70 (0.4 to 1.0) | 0.70 (0.4 to 1.0) |
| RT on D5 | 0.90 (0.50 to 1.2) | 0.83 (0.50 to 1.45) |
| RT on D7 | 1.0 (0.67 to 1.7) | 1.0 (0.68 to 1.6) |
| RT on D14 | 1.6 (1.1 to 2.1) | 1.6 (1.1 to 2.1) |
trend towards oral feed establishment and is measured as overall transfer of milk yo oral out of total amount prescribed
| percentage of volume taken/total volume | Control Group (Group 2) | Intervention Group (Group 1) |
|---|---|---|
| OT on D1 | 21 (15.3 to 36) | 21 (15 to 36) |
| OT on D2 | 35.7 (15 to 36) | 36 (15 to 44) |
| OT on D3 | 43.8 (21 to 50) | 43.8 (21 to 55.5) |
| OT on D5 | 48 (33 to 65) | 48 (33 to 65) |
| OT on D7 | 56 (46 to 100) | 60 (46 to 73.5) |
| OT on D14 | 95.5 (87.9 to 100) | 91 (87 to 100) |
how much amount of milk is taken during first 5 minutes while administering oral feeding
| percentage of volume taken during the fi | Control Group (Group 2) | Intervention Group (Group 1) |
|---|---|---|
| PRO on D1 | 16 (9.2 to 21) | 16 (7.8 to 24) |
| PRO on D2 | 21 (15 to 27) | 21.6 (15 to 32.5) |
| PRO on D3 | 19.5 (14 to 31) | 23 (14 to 37) |
| PRO on D5 | 29 (24.5 to 39) | 30 (25 to 39) |
| PRO on D7 | 39 (32 to 46) | 39 (33 to 49.5) |
| PRO on D14 | 55.8 (46 to 56) | 56 (50 to 60) |
number of neonates who are feeding well and showing coordinated pattern of suck swallow and breath (SSB)
| Participants | Control Group (Group 2) | Experimental Group (Group 1) |
|---|---|---|
| SSB on D1 | 23 | 22 |
| SSB on D2 | 27 | 33 |
| SSB on D3 | 32 | 33 |
| SSB on D5 | 37 | 40 |
| SSB on D7 | 36 | 39 |
| SSB on D14 | 48 | 49 |
monitor for any adverse events like cough, breath holding, chocking, aspiration, tachycardia, and or bradycardia with 1. stimulation 2. feed Adverse outcome monitoring as non-life threatening adverse events including cough, tachycardia HR 180-200/min, bradycardia HR120 - 100/min, , tachypnea RR 60 - 70/min while maintaining SpO2 of \>90% at room air
| Participants | Control Group (Group 2) | Intervention Group (Group 1) |
|---|---|---|
| Adverse events D1 | 31 | 36 |
| Adverse events D2 | 14 | 14 |
| Adverse events D3 | 12 | 12 |
| Averse events D5 | 0 | 2 |
| Adverse events D7 & 14 | 0 | 0 |
Collected over For every neonate adverse events were monitored from first day (D1) of perioral sensory - motor stimulation to day of full oral feed establishment expected by Day 14. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intervention Group (Group 1) | 0/49 (0%) | 0/49 (0%) | 16/49 (32.7%) |
| Control Group (Group 2) | 0/48 (0%) | 0/48 (0%) | 19/48 (39.6%) |
| Event | Intervention Group (Group 1) | Control Group (Group 2) |
|---|---|---|
| Non-life threatening adverse eventsInjury, poisoning and procedural complications | 16/49 | 19/48 |
| Age, Continuous(years) | Intervention Group (Group 1) | Control Group (Group 2) | Total |
|---|---|---|---|
| Median | 29 (26 to 32) | 30 (26.5 to 33) | 29.5 (26.3 to 32.5) |
| Sex/Gender, Customized(Participants) | Intervention Group (Group 1) | Control Group (Group 2) | Total |
|---|---|---|---|
| Count of participants | 49 | 48 | 97 |
| Race and Ethnicity Not Collected(Participants) | Intervention Group (Group 1) | Control Group (Group 2) | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Maternal education(Participants) | Intervention Group (Group 1) | Control Group (Group 2) | Total |
|---|---|---|---|
| Uneducated | 2 | 2 | 4 |
| Primary | 11 | 10 | 21 |
| Secondary | 15 | 20 | 35 |
| Higher | 21 | 16 | 37 |
| mothers with previous preterm neonates(Participants) | Intervention Group (Group 1) | Control Group (Group 2) | Total |
|---|---|---|---|
| Count of participants | 42 | 38 | 80 |
| Maternal Job status(Participants) | Intervention Group (Group 1) | Control Group (Group 2) | Total |
|---|---|---|---|
| home maker | 29 | 31 | 60 |
| job doing | 20 | 17 | 37 |
| hypertensive disorder of pregnancy(Participants) | Intervention Group (Group 1) | Control Group (Group 2) | Total |
|---|---|---|---|
| Count of participants | 29 | 32 | 61 |
| Gestational diabetes mellitus(Participants) | Intervention Group (Group 1) | Control Group (Group 2) | Total |
|---|---|---|---|
| Count of participants | 17 | 17 | 34 |
28 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After approval from the publishing journal once the study has been completed
Supporting information: Study protocol, Statistical analysis plan
Time frame: 1 year after the study's publication for 3 months
Access criteria: on request to corresponding author
Ran from Mar 2022 to primary completion in May 2023, 14 months.
Results were first posted in Dec 2024, 1 year 7 months after primary completion.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 14 months is below that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fatima Memorial Hospital